Name in SEC filings: ARVINAS, INC.
Source: ORION, orionbiotechai.com/company/ARVN, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/ARVN
ARV-102 · Topline/data readout · fourth quarter of 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutfourth quarter of 2026
Stage: Phase 1SEC filing · “Phase 1”
Public float: $469,000,000 · as of · SEC filing
additional biomarker data from the Phase 1 clinical trial in patients with PD at the International Congress on Parkinson’s Disease and Movement Disorders in the fourth quarter of 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Phase 1SEC filing · “Phase 1”
Public float: $469,000,000 · as of · SEC filing
clinical data from the early monotherapy cohorts in the ongoing Phase 1 dose escalation clinical trial of ARV-393 in patients with relapsed/refractory NHL at a medical congress in the second half of 2026
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutsecond half of 2026
Stage: Phase 1SEC filing · “Phase 1”
Public float: $469,000,000 · as of · SEC filing
KRAS G12D mutations. ◦ Reiterated plan to share initial data from the Phase 1 monotherapy dose escalation clinical trial in the second half of 2026
EX-99.1 · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| ARV-102Clinical results | fourth quarter of 2026“additional biomarker data from the Phase 1 clinical trial in patients with PD at the International Congress on Parkinson’s Disease and Movement Disorders in the fourth quarter of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| ARV-393Clinical results | second half of 2026“clinical data from the early monotherapy cohorts in the ongoing Phase 1 dose escalation clinical trial of ARV-393 in patients with relapsed/refractory NHL at a medical congress in the second half of 2026” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| ARV-806Clinical results | second half of 2026“KRAS G12D mutations. ◦ Reiterated plan to share initial data from the Phase 1 monotherapy dose escalation clinical trial in the second half of 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| ARV-102Clinical results | second half of 2026“additional biomarker data from the Phase 1 clinical trial in patients with PD in the second half of 2026” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| ARV-806Clinical results | 2026“initial clinical data in patients with solid tumors harboring KRAS G12D mutations in 2026” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| ARV-806Clinical results | 2026“initial clinical data i n patients with solid tumors harboring KRAS G12D mutations in 2026” Filed · 10-K | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
No historical announcement trail is retained for this company in this catalog.
Original ClinicalTrials.gov record · Open the selected study
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksSuggest an SEC timing statement to add for ARVN. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See ARVN in the calendar · Review labels and methodology